Compare DLNG & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLNG | OVID |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.4M | 117.3M |
| IPO Year | 2013 | 2017 |
| Metric | DLNG | OVID |
|---|---|---|
| Price | $3.82 | $1.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.60 |
| AVG Volume (30 Days) | 43.6K | ★ 1.7M |
| Earning Date | 11-20-2025 | 11-12-2025 |
| Dividend Yield | ★ 5.22% | N/A |
| EPS Growth | ★ 30.14 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $158,275,000.00 | $6,610,000.00 |
| Revenue This Year | N/A | $1,077.56 |
| Revenue Next Year | $0.37 | N/A |
| P/E Ratio | $2.91 | ★ N/A |
| Revenue Growth | 4.34 | ★ 945.89 |
| 52 Week Low | $3.18 | $0.24 |
| 52 Week High | $5.65 | $2.01 |
| Indicator | DLNG | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 64.02 | 55.94 |
| Support Level | $3.71 | $1.45 |
| Resistance Level | $3.84 | $1.75 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 96.05 | 67.22 |
Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.